Acetazolamide

Quick links to important sections

Acetazolamide

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acetazolamide

Property Description
Active ingredient Acetazolamide
Form Oral tablets, capsules, intravenous solution
Pharmacological class Carbonic Anhydrase Inhibitor (CAI)
General purpose Fluid excretion and pressure modulation
Origin Synthetic, Sulfonamide derivative

Acetazolamide is a synthetic, single-active-ingredient pharmaceutical agent classified as a specific type of diuretic and, more precisely, as a Carbonic Anhydrase Inhibitor (CAI). Chemically, the compound is identified as a non-bacteriostatic sulfonamide derivative. This agent is used for its capacity to affect fluid and acid-base balance by inhibiting a specific enzyme, which leads to various systemic effects.

What Type of Medicine is Acetazolamide?

Acetazolamide belongs to the Carbonic Anhydrase Inhibitor (CAI) pharmacological class. This classification dictates the drug's primary action of inhibiting the carbonic anhydrase enzyme, which is critical for electrolyte balance. The drug is manufactured as a prescription-only medicine, originating from a synthetic chemical process. This classification is key to its action, distinguishing it from other types of diuretics that operate through different mechanisms. The general therapeutic approach of using a CAI like Acetazolamide is clinically recognized for managing conditions where internal pressure requires precise adjustment.

Forms, Origin, and Primary Action

Acetazolamide is supplied primarily as oral tablets and oral capsules, including extended-release formulations, allowing for administration through the oral route. It is also available as a lyophilized powder intended for the intravenous (IV) route, requiring reconstitution for parenteral use, a method often reserved for instances requiring rapid adjustment. The primary action involves blocking the carbonic anhydrase enzyme, which influences fluid dynamics and internal pressure levels throughout the body.

What is the General Purpose of Acetazolamide?

The general pharmacological purpose of Acetazolamide is to promote the excretion of excess salts and water, acting as a specialized diuretic, while simultaneously functioning as an agent for pressure modulation. The drug’s unique systemic mechanism allows it to regulate fluid volume and help relieve pressure buildup in specific fluid-filled compartments of the body. This drug is often considered a foundational treatment in scenarios where reduction of fluid secretion, such as in the eye or brain, is necessary.

Regulatory References

  1. Acetazolamide - StatPearls - NCBI Bookshelf - NIH
  2. Acetazolamide MeSH Descriptor Data
  3. Acetazolamide: MedlinePlus Drug Information
  4. Acetazolamide - eEML - Electronic Essential Medicines List

What side effects are possible with Acetazolamide?

Possible Side Effects and Safety Information

The safety profile of Acetazolamide is defined by distinct regulatory classifications that organize the nature and incidence of potential adverse reactions. This information is derived exclusively from official government-approved prescribing labels.


Officially Documented Adverse Reactions

Adverse effects are categorized by frequency and the body system affected (System-Organ-Class).

Very Common reactions (occurring in 10% or more of patients) primarily include Paresthesia (a tingling or 'pins and needles' sensation), which is often noted in regulatory documents as dose-related.

Common reactions (affecting 1% to 10% of patients) cover effects such as Polyuria (increased urination), anorexia, taste disturbances (especially for carbonated beverages), headache, dizziness, and fatigue. Polyuria and associated electrolyte disturbances are typically more prominent at the start of treatment.

Serious adverse reactions are rare but are officially listed, particularly due to the drug’s sulfonamide structure. These include potentially fatal conditions such as Aplastic Anemia and other severe Blood Dyscrasias, as well as severe skin reactions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

Safety Restrictions and Monitoring

Acetazolamide is formally contraindicated (should not be used) in patients with severe renal impairment or severe hepatic impairment (e.g., cirrhosis), as documented in prescribing information. These restrictions address the risk of drug accumulation and the potential to precipitate conditions like hepatic encephalopathy. Regulatory labels advise for periodic monitoring of blood cell counts and serum electrolytes during therapy to observe for potential adverse reactions.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information states that there are no data available regarding acute Acetazolamide overdosage in humans, as no cases of acute poisoning have been reported. Nevertheless, an overdose is anticipated to result in significant physiological disturbances, primarily the development of an acidotic state and pronounced electrolyte imbalance, potentially leading to central nervous effects.

Required Emergency Actions

The regulatory guidance mandates that treatment should be symptomatic and supportive, with the specific goal of restoring both electrolyte and pH balance. Because no specific antidote is known, continuous monitoring of serum electrolyte levels (specifically potassium) and blood pH levels is required during management.

Immediate medical attention must be sought for any suspected overdose or if severe adverse reactions occur. Life-threatening complications, such as coma or death, have been officially reported in cases of severe toxicity, particularly when Acetazolamide is administered concomitantly with high-dose aspirin.

Therapeutic Uses of Acetazolamide

Acetazolamide is generally used to address symptom patterns driven by specific fluid and pressure imbalances across several key clinical domains. The medication provides supportive therapeutic benefit by helping to moderate distressing manifestations and contributes to easing the overall symptom burden.

This agent is commonly used across conditions characterized by increased physiological stress, including the management of glaucoma (high intraocular pressure), reduction of edema (swelling) associated with congestive heart failure, mitigation of Acute Mountain Sickness (AMS) symptoms, and as supplementary support for certain recurrent seizure disorders (epilepsy). It is applied in clinical settings that involve acute or unstable symptom patterns, helping to stabilize function.

“A key therapeutic benefit of this medication is its role in assisting patients with coping more steadily with difficult, pressure-related, or episodic manifestations.”


Key Therapeutic Domains

The medication is generally considered relevant for easing symptoms related to:

  • Elevated Internal Pressure: Applied in situations requiring sustained control to support the maintenance of visual function and may assist in easing pressure-related headaches and visual disturbances.
  • Fluid Overload: Supports patients by contributing to physical comfort and easing the functional strain caused by systemic swelling and fluid retention.

Symptom Focus: Supporting Relief for Pressure-Related Headaches

Acetazolamide is commonly used to help with symptoms of Idiopathic Intracranial Hypertension (IIH) and Acute Mountain Sickness, conditions where headaches are a prominent manifestation of internal pressure or physiological imbalance.

Regulatory References

  1. NIH MedlinePlus overview of Acetazolamide

Eligibility and Restrictions for Use

Who Can and Cannot Use Acetazolamide?

Eligibility for Acetazolamide use is strictly determined by regulatory labeling, which outlines specific contraindications, limitations, and special population considerations.


Absolute Contraindications (Must Not Use)

Acetazolamide is strictly contraindicated in patients with a known hypersensitivity to the drug or to sulfonamide derivatives. Use is also prohibited in individuals with severe renal dysfunction (kidney failure), marked hepatic dysfunction (severe liver disease/cirrhosis), adrenocortical insufficiency, and pre-existing electrolyte imbalances, specifically hyperchloremic acidosis, hyponatremia, or hypokalemia.


Populations Requiring Restricted Use

Population Category Regulatory Status
Pregnancy Not recommended, especially during the first trimester. Use is restricted to cases where the benefit justifies the risk.
Breastfeeding/Lactation Not recommended due to excretion into human milk.
Older Adults (Geriatric) Use requires caution due to a higher frequency of decreased organ function (renal, hepatic, or cardiac).
Pediatric Patients Safety and effectiveness are not established for all indications.
Chronic Angle-Closure Glaucoma Long-term administration is contraindicated as it may mask the condition's progression.

Condition-Specific Restrictions

Caution is advised for patients with chronic lung disease where alveolar ventilation is impaired, due to the risk of aggravating acidosis. Use also requires consideration in patients with Diabetes Mellitus or a history of renal calculi.

What should I know about interactions with other medicines?

Acetazolamide Interactions with other medicines and products

The official interaction profile for Acetazolamide, a carbonic anhydrase inhibitor, is characterized by significant pharmacokinetic and pharmacodynamic constraints documented by regulatory authorities.


Interaction Scope and Restrictions

The regulatory documents define specific high-risk combinations. Co-administration is strictly contraindicated with High-dose Aspirin or Salicylates due to the officially documented risk of severe metabolic acidosis and increased CNS toxicity. The combination with Methenamine is also prohibited, as it can form an insoluble precipitate in the urine. Concurrent use with other Carbonic Anhydrase Inhibitors is not advised due to potential additive effects.


Exposure Modification

Acetazolamide modifies the clearance of several co-administered medicinal products, primarily by altering urinary pH. This mechanism decreases the urinary excretion of alkaline drugs, such as Amphetamines and Quinidine, which may enhance their effects. Conversely, it increases the excretion of Lithium, potentially reducing its concentration. Furthermore, Acetazolamide may increase the serum levels of Phenytoin and Cyclosporine, which are documented as clinically significant exposure alterations.


Population and Timing Notes

Use is contraindicated in patients with marked liver disease or renal dysfunction because these conditions amplify the risk of severe complications like hepatic encephalopathy. Food does not affect the bioavailability of the extended-release formulation. There are no mandatory time separation requirements explicitly written in the core regulatory labels.

Mechanism of Action

How Acetazolamide Works: Mechanism of Action

Acetazolamide functions as an enzyme inhibitor, specifically targeting carbonic anhydrase (CA). This mechanism modulates physiological processes related to acid-base balance and fluid secretion across multiple body systems.

Molecular and Intracellular Action

The drug works by binding reversibly to and inhibiting carbonic anhydrase, an enzyme critical for catalyzing the conversion of carbon dioxide ( CO2) and water ( H2 O) into bicarbonate ( HCO3^-) and hydrogen ions ( H^+). This action directly modifies early molecular steps by limiting the availability of these essential ions for transport and buffering.

System-Level Physiological Modulation

Inhibition of CA within the renal proximal tubules prevents the efficient reabsorption of HCO3^- back into the bloodstream. This leads to an increased renal excretion of HCO3^- and associated electrolytes, including sodium ( Na^+) and water. Additionally, by inhibiting CA in the ciliary body of the eye and the choroid plexus of the brain, Acetazolamide reduces the rate of fluid formation of aqueous humor and cerebrospinal fluid (CSF), respectively. The limitation of fluid formation results in a reduction of pressure within these compartments.

Dosage and Administration Information

Acetazolamide is administered via the oral route as immediate-release tablets or extended-release capsules, and parenterally via the intravenous (IV) route using a powder for injection. The direct IV method is the preferred parenteral route, as intramuscular injection is not generally recommended.

Standardized Dosing and Schedules

Adult oral dosing varies by use, typically ranging from 250 mg to 1 g daily. For glaucoma, the maximum effective dosage is generally 1 g per 24 hours, and daily amounts over 250 mg are administered in divided doses. When managing fluid retention (edema), a starting dose of 250 mg to 375 mg is often given once daily in the morning. This use is often managed on an intermittent schedule of alternate days or two days followed by a rest day, a pattern intended to sustain the desired effect. For use related to high altitude, the regimen is typically initiated 24 to 48 hours before ascent and continued for 48 hours while at elevation.

Administration Logistics and Constraints

Oral tablets and capsules may be taken with or without food. Extended-release capsules are designed to be swallowed whole to preserve the controlled-release pattern. For IV administration, the 500 mg powder vial is prepared by adding at least 5 mL of Sterile Water for Injection prior to use. Dosage adjustment or avoidance is officially recommended for older adults and populations with marked impairment of renal or hepatic function. Dosing in children is based on body weight or surface area, with specific limits defined in regulatory documentation.

Recent Clinical Evidence

Acetazolamide: Recent Clinical Evidence

Overview of Clinical Research

Acetazolamide is a carbonic anhydrase inhibitor with established uses in managing glaucoma, altitude sickness, and certain forms of epilepsy. Recent clinical investigations have explored its role as an adjunctive diuretic therapy in managing acute decompensated heart failure (ADHF) with volume overload.


Core Studies on Efficacy

The largest recent evidence base includes a multinational, randomized, placebo-controlled trial (e.g., the ADVOR trial) that focused on patients hospitalized with ADHF.

Decongestion and Diuresis

  • Studies investigated whether adding acetazolamide to standard-of-care loop diuretics was associated with successful early decongestion in patients with ADHF. The primary outcome was successful decongestion achieved within three days of randomization.
  • Analyses also reported that the addition of the drug was associated with increased natriuresis (sodium excretion) and diuresis (urine output), as compared to the placebo group.

Patient Outcomes

  • The same studies examined secondary outcomes and found that the group receiving acetazolamide was associated with a shorter length of hospital stay.
  • Evidence regarding all-cause mortality, rehospitalization rates, and quality of life scores at three months post-discharge did not show a statistically significant difference between the drug and placebo groups.

Safety and Patient Considerations

  • Safety profiles assessed during these large trials generally reported that the drug was well-tolerated.
  • The most commonly noted side effect in the acetazolamide group was a higher rate of hypokalemia (low potassium levels) compared to the placebo group. Close monitoring of electrolytes is typically required.

Pharmacodynamics and Mechanism

Research included investigations into the drug's mechanism, which involves inhibiting carbonic anhydrase activity in the proximal tubules of the kidney. This action promotes the urinary excretion of sodium and bicarbonate, supporting the action of loop diuretics to enhance fluid removal.

Frequently Asked Questions (FAQ)

Common questions about Acetazolamide (FAQ)

Q: How quickly can a person expect Acetazolamide to start working for altitude sickness?

A: According to official prescribing information, the immediate-release tablet typically results in maximum therapeutic effect between one and four hours after a dose. The duration of this effect is usually 8 to 12 hours. For the extended-release capsule, maximum effect is expected 3 to 19 hours following administration, with effects lasting up to 18 to 24 hours.

Q: What happens if a person misses a dose of Acetazolamide?

A: General guidance provided in official patient information states that a missed dose should be taken as soon as it is remembered. If it is nearly time for the next scheduled dose, official information indicates that taking the missed dose may be omitted to resume the regular schedule. Regulatory patient documents generally state that doubling the dose to compensate is not recommended.

Q: Is it true that Acetazolamide can affect the taste of carbonated drinks?

A: Yes, official safety information lists taste disturbances, known technically as dysgeusia, as a common adverse reaction. The safety information notes that this effect is commonly described by users as a change in the taste of carbonated beverages.

Q: Does Acetazolamide usually cause tiredness or fatigue?

A: Official safety documents list both fatigue (tiredness) and drowsiness as common adverse reactions. This means a percentage of patients using the medicine are likely to experience these effects. Official safety profiles indicate that effects like these are sometimes reported at the start of treatment.

Q: How long does the effect of a single dose of Acetazolamide typically last?

A: The duration of the drug’s effect depends on the formulation used. The effect of a single immediate-release tablet dose typically lasts 8 to 12 hours. The extended-release capsule formulation is designed to maintain its effect for 18 to 24 hours.

Q: What are the general guidelines for stopping Acetazolamide after a course of treatment?

A: In certain uses, such as for seizure treatment, regulatory information advises that Acetazolamide should be withdrawn gradually. This practice is described as intended to minimize the risk of seizure worsening or the development of status epilepticus. The regulatory context for discontinuing the medication varies depending on the specific condition being managed.

Q: Are there any common foods or drinks that should be avoided while taking Acetazolamide?

A: Regulatory patient information advises limiting the consumption of alcoholic beverages while using Acetazolamide. This is because alcohol can potentially increase the severity of central nervous system side effects, such as dizziness or drowsiness, which are already associated with the medication.

Q: Can Acetazolamide change the way other medications work in the body?

A: Yes, regulatory documents describe that Acetazolamide can modify the effects of co-administered drugs. This is primarily because it changes the urinary acidity (pH), which alters how the body clears other medicines. This action can enhance the effects of some alkaline drugs, like quinidine, while increasing the excretion of others, like lithium.

Q: Are there any long-term effects associated with using Acetazolamide for many months?

A: When Acetazolamide is used for an extended period, official warnings list potential risks such as an increased incidence of kidney stone formation, known as nephrolithiasis. For this reason, the long-term use requires periodic monitoring of blood cell counts and serum electrolytes.

Q: Can Acetazolamide affect kidney function over time?

A: Regulatory documents list the potential for adverse effects on the renal system, including rare but serious issues such as renal failure. The risk of kidney stone formation is also reported to be increased with long-term therapy. The medication is strictly contraindicated for individuals who already have severe kidney impairment.

Q: How does Acetazolamide relate to the treatment of epilepsy or seizures?

A: Acetazolamide is an officially approved medication for the adjunctive (additional) treatment of specific types of seizures. This includes certain forms of grand mal seizures, absence seizures, and other mixed seizure patterns.

Q: Can the effectiveness of Acetazolamide decrease after long-term use?

A: Official patient information notes that when Acetazolamide is used continuously over a long period, its effectiveness may diminish. This is a common pattern for its diuretic effects, meaning the medication might not work as well over time.

Q: Does Acetazolamide usually need to be taken at a specific time of day?

A: For specific indications, such as promoting fluid removal (diuresis) in congestive heart failure, official dosing instructions specify that the dose is usually taken once daily in the morning. This is intended to align with typical daily activity and sleep cycles.

Q: Can older adults use Acetazolamide, and are there specific concerns?

A: Official information states that use in older adults requires caution. This is because geriatric patients may be more sensitive to the drug’s effects, such as dizziness and lightheadedness, due to the higher likelihood of pre-existing decreased organ function (kidney or liver).

Q: What should be known about Acetazolamide use while traveling?

A: Acetazolamide is officially indicated for the prevention or reduction of symptoms related to acute mountain sickness (AMS) during travel to high altitudes. Regulatory information specifies that the drug does not replace clinical practices such as gradual ascent, or the need for prompt descent if severe symptoms of AMS occur.

Q: Can Acetazolamide cause changes in mood or confusion?

A: Official safety information lists confusion and drowsiness as common adverse reactions associated with the use of Acetazolamide. These are central nervous system effects that can impact mental clarity and mood.

Q: Is Acetazolamide known to cause skin sensitivity to the sun?

A: Yes, official regulatory documents and patient information note that Acetazolamide may cause photosensitivity, which is an increased sensitivity of the skin to sunlight. Due to this risk, the regulatory patient information often suggests using protective clothing and sunscreen when exposed to the sun.

Q: What is the relationship between Acetazolamide and potassium levels?

A: Acetazolamide's mechanism of action is known to cause electrolyte imbalances, specifically resulting in hypokalemia, or low potassium levels. This is a consequence of its diuretic effect. Due to this risk, periodic monitoring of serum electrolytes is recommended during treatment.

Q: Are there any known issues with Acetazolamide and certain chronic health conditions?

A: Yes, the drug is strictly contraindicated for individuals with severe kidney disease, severe liver disease (such as cirrhosis), and adrenal gland insufficiency. Official documents also advise using caution for patients with severe breathing difficulties or pre-existing diabetes mellitus.

Q: Can Acetazolamide be used by people who have diabetes?

A: Acetazolamide should be used with caution in individuals who have diabetes mellitus. This is because the medication has been documented to cause fluctuations in blood glucose levels, including both increases and decreases, which requires careful monitoring.

Q: Why is Acetazolamide not recommended for people with severe liver problems?

A: The drug is contraindicated (should not be used) in patients with marked hepatic dysfunction because of the potential risk of precipitating hepatic encephalopathy. This is a severe complication affecting brain function that is noted in regulatory warnings.

Q: Is Acetazolamide considered safe for people who drive or operate machinery?

A: Adverse reactions like drowsiness, fatigue, and blurred vision may impair the ability to drive or operate machinery. Official information states that due to these risks, patients should refrain from driving or operating machinery until they understand how the medication affects them.

Q: Can Acetazolamide be used to treat fluid retention in heart failure?

A: Yes, regulatory documents list Acetazolamide as indicated for the adjunctive treatment of edema, which is fluid retention, associated with congestive heart failure. Adjunctive means it is used as an addition to other standard therapies.

Q: Does Acetazolamide affect electrolyte balance in the body?

A: Yes, the action of the drug's mechanism causes the body to lose bicarbonate and associated electrolytes, including sodium and potassium, through the kidneys. This can result in documented electrolyte imbalances, such as hyponatremia (low sodium) and hypokalemia (low potassium).

Q: Is there any research into new uses for Acetazolamide?

A: Official documents list the established uses, including glaucoma, epilepsy, and altitude sickness. However, research has also investigated the drug's potential role in managing other conditions, such as idiopathic intracranial hypertension and periodic paralysis.

Q: Are children eligible to use Acetazolamide, and under what conditions?

A: The drug is indicated for use in children for certain types of seizures, with specific weight-based dosing and limits defined in regulatory documents. However, official information also states that safety and effectiveness are not established for all indications in pediatric patients.

Q: Is the use of Acetazolamide in women who are breastfeeding described in official sources?

A: Yes, official regulatory documents confirm that Acetazolamide is excreted into human milk. Therefore, its use is generally not recommended for women who are currently breastfeeding.

Q: Can Acetazolamide affect sleep patterns?

A: Adverse reaction lists in regulatory documents include drowsiness, which is a common central nervous system effect. Drowsiness can potentially influence an individual's sleep patterns.

Q: What is Acetazolamide's role in treating periodic paralysis?

A: Official indications and usage information notes that Acetazolamide is utilized for the treatment of certain forms of periodic paralysis.

Q: Are there warnings about using alcohol while taking Acetazolamide?

A: Yes, official patient information advises limiting the consumption of alcoholic beverages. The reason is that alcohol can increase the risk of central nervous system side effects associated with the drug, such as dizziness or drowsiness.

Q: How is Acetazolamide different from other 'water pills'?

A: Acetazolamide is classified as a carbonic anhydrase inhibitor (CAI), which gives it a distinct mechanism of action. Official information specifically distinguishes it from other historical types of diuretics, such as mercurial diuretics.

Q: Is there a maximum time Acetazolamide can be used according to regulatory data?

A: Continuous, long-term administration is specifically contraindicated for patients with chronic non-congestive angle-closure glaucoma, as it may hide the condition's progression. For other uses, the drug is not generally prescribed for longer than necessary, and extended use requires periodic monitoring.

Q: Can Acetazolamide affect blood pressure?

A: The drug’s diuretic action can influence fluid volume and electrolytes, which in turn affects the circulatory system. Documented drug interactions and uses in conditions like heart failure suggest effects on blood pressure, including a noted potential for hypotension (low blood pressure) in combination with certain other drugs.

Q: Do many people experience tingling or numbness (paresthesia) when taking Acetazolamide?

A: Yes, regulatory documents list paresthesia, which is the tingling or 'pins and needles' sensation, as a very common adverse reaction. This means the effect is reported to occur in 10% or more of patients using the medication.

How should Acetazolamide be stored and disposed of?

Storage Requirements

Acetazolamide tablets, capsules, and unmixed injectable powder must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The oral formulation must be kept in the original, tightly closed container to ensure protection from light and moisture. All forms must be stored out of the sight and reach of children.

Stability and Handling

The intravenous (IV) powder for injection must also be stored at Controlled Room Temperature but requires special handling after mixing. The reconstituted solution must be stored refrigerated at 2 C to 8 C (36 F to 46 F) and must be discarded after 12 hours of reconstitution, as it contains no preservative.

Disposal Instructions

Any unused or expired Acetazolamide product, including the unused portion of the injectable solution, must be disposed of in accordance with local requirements. Regulatory guidelines often specify disposal through an authorized take-back program or special procedures to prevent discarding medicine into household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acetazolamide found in:

A-Z Index: